Novartis has started construction on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23bn investment in US manufacturing and research. The start of construction on the company’s first Texas-based manufacturing facility brings US RLT production closer to patients across the southern US, becoming the fifth RLT site nationwide.
Vas Narasimhan, CEO of Novartis, said: “Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale.
“Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalised treatments when and where they need them.”
Announced earlier this year, the site is expected to become operational in 2028 and create new US-based Novartis jobs in bioengineering, advanced manufacturing, quality and operations.
The Texas facility bolsters the Novartis coast-to-coast RLT manufacturing network, with existing US sites in New Jersey, Indiana and California, and a new site being added in Florida. The Denton site adds to the largest US RLT manufacturing network and further builds on the company’s longstanding track record of enabling >99% of doses to be administered on the planned day of treatment. Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centres critical to delivering treatment as planned.
In April 2025, Novartis committed $23bn over five years to grow its US research and manufacturing footprint. Seven new and three expanded facilities across the country are already under construction – part of the company’s broader effort to manufacture all key medicines for US patients in the US, supporting supply resilience and dependable delivery of medicines.